Novaccess Global Inc - XSNX STOCK NEWS

Dr. Christopher Wheeler, lead scientist at NovAccess Global (OTCQB:XSNX), received the prestigious Golden Axon Award at the World Brain Mapping Foundation Annual Congress on February 17, 2023. This award honors individuals who significantly contribute to brain mapping and neuroscience. Dr. Wheeler, along with CEO Dr. Dwain Irvin, presented NovAccess's research on immune targets and therapies for malignant brain tumors. NovAccess focuses on developing innovative cancer therapies, including a vaccine aimed at enhancing immune response against brain tumors. The event connected key figures in neuroscience and raised awareness for critical health issues.

NovAccess Global (OTCQB:XSNX), a biomedical firm focused on immunotherapies for brain tumors, announced CEO Dr. Dwain Irvin's invitation to present at the World Orphan Drug Congress from May 23-25, 2023, near Washington, DC. The company gained FDA Orphan Drug Designation for its TLR-AD1 vaccine, targeting aggressive brain cancers like glioblastoma. This designation could expedite therapy development for glioblastoma patients. The congress will enable NovAccess to share its advancements with industry leaders and foster partnerships. The event is pivotal for orphan drug development, featuring over 300 speakers.

NovAccess Global Inc. (OTCQB:XSNX) announced its CEO Dr. Dwain Irvin and Dr. Christopher Wheeler, Lead Scientist, will present at the World Brain Mapping Foundation Annual Congress on February 17, 2023, in Los Angeles, CA. The event recognizes contributions in neuroscience and aims to foster connections among industry leaders. Dr. Wheeler will receive a leadership award for his role in organizing the conference. NovAccess will present its advancements in vaccine immunotherapy for malignant brain tumors, emphasizing the company’s dedication to improving treatment options for brain tumor patients.

NovAccess Global Inc. (OTCQB:XSNX) has launched its latest fireside chat featuring Dr. Christopher Wheeler, discussing the advantages of immunotherapy over surgical treatment for brain tumors. The chat highlights the TLR-AD1 therapy, currently at the IND filing stage, which aims to enhance the immune response against cancer cells. In October 2022, the company received FDA Orphan Drug Designation for TLR-AD1, providing potential access to non-dilutive funding. The series aims to cover relevant healthcare innovations, with future discussions planned on glioblastoma treatment.

NovAccess Global Inc. (OTCQB:XSNX) has launched a monthly fireside chat series aimed at discussing immunotherapy's benefits over traditional chemotherapy for brain tumor patients. The initial interview features CEO Dr. Dwain Irvin and cancer advocate Cori Freeman, focusing on treatment experiences and the limitations of conventional options. Key points include the advancements in immunotherapy research, particularly the FDA-approved TLR-AD1 drug candidate, aimed at improving survivability and quality of life for glioblastoma patients. The series will continue monthly through January 2023.

NovAccess Global Inc. (OTCQB:XSNX) has appointed Dr. Peter Weinstein to its Scientific Advisory Board. Dr. Weinstein, an intellectual property attorney and healthcare consultant, has worked with NovAccess's subsidiary, StemVax Therapeutics, for several years. His expertise spans biotechnology, healthcare IT, and oncology drug development. Dr. Weinstein holds a Ph.D. in biology and a JD, and has a rich background in patent management. This appointment aims to enhance the protection of NovAccess's intellectual property and bolster its strategic development in cancer therapies.

NovAccess Global Inc. (OTCQB:XSNX) will hold its annual shareholders' meeting virtually on November 21, 2022, at 11:00 AM ET. Shareholders of record as of the close of business on November 11, 2022 are eligible to vote. The meeting will cover voting procedures and feature a management presentation.

Participants can join via Zoom or phone. Questions can be submitted prior to the meeting. This meeting aims to engage shareholders and provide insights into the company’s ongoing projects.

NovAccess Global announced FDA approval of its Orphan Drug Designation for TLR-AD1, a vaccine aimed at treating glioblastoma and other high-grade gliomas. This milestone accelerates their plans for an Investigational New Drug (IND) application, expected to be submitted in the first half of 2023. Glioblastoma currently affects approximately 250,000 individuals globally each year, with a treatment market valued over $2 billion in 2020 and an anticipated growth rate of over 8%. Orphan designation promises benefits such as tax credits and development assistance for this innovative therapy.